Do apple cider vinegar (ACV) gummies reduce appetite in generally healthy adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Apple Cider Vinegar Gummies for Appetite Control

Apple cider vinegar gummies should not be recommended for appetite suppression, as the only available evidence shows that any appetite-reducing effects of vinegar are due to nausea and poor tolerability rather than a legitimate physiological mechanism.

Evidence Against ACV for Appetite Control

The single relevant study examining vinegar's effects on appetite demonstrates a concerning mechanism of action 1:

  • Vinegar ingestion reduced appetite only when it caused nausea, with the most unpalatable vinegar preparations having the greatest appetite-suppressing effect 1
  • Significant correlations existed between poor palatability ratings and appetite reduction, indicating the effect was mediated by gastrointestinal distress rather than beneficial metabolic changes 1
  • When vinegar was only tasted without swallowing (orosensory stimulation alone), it had no effect on appetite, confirming that ingestion-induced nausea was the sole mechanism 1

Clinical Implications

The research explicitly concludes that "the promotion of vinegar as a natural appetite suppressant does not seem appropriate" given that effects are driven by tolerability issues 1. This finding is particularly relevant for gummy formulations, which are designed to be palatable and well-tolerated—thereby eliminating the very mechanism (nausea) responsible for any appetite effects seen with liquid vinegar.

Evidence-Based Alternatives

If appetite suppression for weight management is the clinical goal, FDA-approved medications with legitimate mechanisms exist 2:

  • GLP-1 agonists (liraglutide 3.0 mg) work through multiple physiological pathways including increased satiety, slowed gastric emptying, and suppression of postprandial glucagon, achieving 5.4% weight loss at 56 weeks 2
  • Phentermine/topiramate ER achieves 9.8-10.9% weight loss at one year, significantly superior to other agents 2
  • All pharmacologic interventions must be combined with reduced-calorie diet and increased physical activity 2

Common Pitfall

Avoid recommending supplements marketed for appetite control without legitimate evidence of efficacy through beneficial mechanisms, particularly when the only documented effects are mediated by adverse gastrointestinal symptoms 1.

References

Guideline

Visceral Fat Reduction with Medications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the best way to obtain a second opinion on imaging studies while preserving a collaborative relationship with my current care team?
Can a 12-year-old patient weighing 46 kg receive an adult dose of medication?
To what temperature should a mother warm an infant's bottle for feeding?
Are infirmaries ineffective because they cannot fully treat patients' conditions due to limited facilities and diagnostic tests?
Can decreased urethral pressure cause an uncontrolled urinary stream?
What are the approved indications for rivaroxaban (Rivaban)?
What is the appropriate treatment for seborrheic dermatitis?
How should prednisone be started, dosed, tapered, and monitored for rheumatoid arthritis?
What is the diagnosis and recommended management for a 36-year-old woman presenting with an irregular pulse, recent febrile episodes, a history of sore throat, elevated antistreptolysin‑O titre, and moderate mitral regurgitation on echocardiogram with normal left‑ventricular size and systolic function?
How should the management plan be modified for a 50‑year‑old post‑menopausal woman with multiple sclerosis (treated with lymphocyte infusions), controlled hypothyroidism on levothyroxine 50 µg, no other significant comorbidities, who presents with occasional daytime palpitations and an electrocardiogram confirming atrial fibrillation?
In a patient with type 2 diabetes, what are the differences between a glucose‑dependent insulinotropic polypeptide (GIP)/glucagon‑like peptide‑1 (GLP‑1) dual agonist (e.g., tirzepatide) and a glucagon‑like peptide‑1 (GLP‑1) only agent (e.g., semaglutide, dulaglutide, liraglutide)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.